Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Race for Top Brands for BPH Tightens as Generics Make Inroads; OAB Market Grows as Disease Entity Becomes Better Defined
October 25, 2013
- Ono Licenses Pheochromocytoma Treatment Metyrosine from Valeant
October 24, 2013
- Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
- Shionogi, Nipro to Copromote Anti-Influenza Treatment Rapiacta
October 23, 2013
- Roche Still Tops in Patent Asset Ranking in Japan, Shionogi, MTPC Jumps to Second, Third Place
October 22, 2013
- Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey
October 22, 2013
- BMKK, Pfizer to Change Distribution Channel to Wholesalers for Eliquis, Remain as Copromoters
October 21, 2013
- CMIC Holdings Joins Hands with UK Firm Aesica in Contract Manufacturing Biz
October 21, 2013
- Santen Opens Office in Ho Chi Minh City
October 21, 2013
- Kissei, Kyorin Initiate PI Study of Overactive Bladder Treatment KEA-0447/KRP-EPA605
October 21, 2013
- Teva Pharma Japan to Discontinue Marketing 15% of All Products Under Selection and Concentration Strategy
October 18, 2013
- Amgen Making Fresh Start in the Japanese Market through Joint Venture with Astellas; Pathway to Independent Operation Remains Nebulous
October 18, 2013
- Eisai Inc to Increase Belviq Sales Reps to 400 in US
October 17, 2013
- Toho Pharmaceutical’s Logistics Base TBC Sapporo Starts Operations: Toho Holdings
October 17, 2013
- NBI, Eli Lilly Submit NDA for SGLT-2 Inhibitor
October 17, 2013
- Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
- Otsuka Completes Acquisition of US Biotech Startup Astex
October 16, 2013
- Janssen, AZ to Copromote Prostate Cancer Treatment Abiraterone in Japan
October 16, 2013
- Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market
October 15, 2013
- Santen Launches Preservative-Free Tapros Mini Ophthalmic Solution
October 15, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…